the American Academy of Palliative Medicine (Thomas JR et al. J Pall
Med. December 2007; 19(6):1312-1320). The authors of this publication
concluded from this volunteer subject study that clinically relevant
fluid volumes can be rapidly delivered subcutaneously with HYLENEX in a
well-tolerated manner without the need for an infusion pump. The
findings suggest that this method of hydration could potentially
replace intravenous infusions in many clinical settings and that
further studies with HYLENEX, in patients, are warranted.
-- The addition to the NASDAQ Biotechnology Index(R) (Nasdaq: NBI) on
November 19, 2007. Launched in 1993, the NASDAQ Biotechnology Index is
ranked on a semi-annual basis in May and November and serves as the
basis for the iShares NASDAQ Biotechnology Fund (Amex: IBB).
Securities included in the NASDAQ Biotechnology Index must be listed on
the NASDAQ National Market and be classified according to the FTSE(TM)
Global Classification System as either biotechnology or pharmaceutical.
Additionally, securities in the index must meet minimum requirements
for market value, average daily share volume and seasoning as a public
company, among other criteria. For more information about the NASDAQ
Biotechnology Index, including eligibility criteria, visit
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved